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Rheumatoid arthritis as a complex trait
Rheumatoid arthritis (RA) is a condition characterized by 
chronic  inflammation  and  proliferation  of  synovial 
membranes.  The  disease  has  a  worldwide  distribution, 
although it appears to show higher prevalence rates in 
specific populations (for example, indigenous Americans 
[1]). A strong genetic component is suspected, based on 
twin  studies,  studies  of  specific  gene  loci  (such  as  the 
human  leukocyte  antigen  (HLA)  locus),  and,  more 
recently,  gene  linkage  and  genome-wide  association 
studies [2,3]. Patients are heterogeneous in their clinical 
presentation, clinical course, response to therapy, and co-
morbidities such as premature atherosclerosis [4] and an 
increased risk for specific cancers [5,6]. Together, these 
features  make  RA  a  paradigmatic  ‘complex  trait’  and 
amenable to investigation using systems biology approaches 
(that is, approaches designed to acquire a global view of 
the  disease  process  rather  than  focus  on  specific  cell 
interactions  or  metabolic  pathways).  Indeed,  given  its 
complexity,  it  seems  unlikely  that  unraveling  the  most 
compelling  and  vexing  questions  about  RA  will  occur 
using the ‘single receptor-single pathway’ approach that 
has  been  successful  in  other  branches  of  biology  and 
medicine.
The ‘completion’ of the Human Genome Project held 
great promise, but, unfortunately, elucidating the sequence 
of  the  human  genome  has  not  led  to  as  complete  an 
understanding of cell biology and human disease as some 
thought  it  would.  However,  the  undertaking  of  major 
efforts to elucidate genome function, particularly func-
tional aspects of non-coding regions of the genome (for 
example, the National Institutes of Health Encyclo  pedia 
of DNA Elements (ENCODE) project), carries with it the 
potential to provide pathogenic insights that the under-
standing of the sequence and sequence variants has not. 
The application of these new results carries the potential 
to  revolutionize  our  understanding  of  complex  human 
conditions  such  as  RA.  Thus,  any  survey  of  where  we 
have gone and where we might go in the use of systems 
biology and functional genomics to understand RA must 
be informed by the rich and exciting wellspring of data 
emerging from model organisms and ongoing efforts to 
decipher all the functional regions of the human genome.
Gene expression profiling: progress in disease 
classification and response to therapy
It  became  clear  from  the  early  applications  of  gene 
expression  profiling  in  oncology  that  this  technology 
would be very useful for answering disease classification 
questions  [7].  In  2003,  van  der  Pouw  Kraan  et  al.  [8] 
studied  gene  expression  in  RA  synovium  and  found 
evidence for adaptive immune responses in some patients 
with RA, and fibroblast anomalies in others. A year later, 
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to reveal the complexity of the transcriptome. In 
addition to serving as passive templates from which 
genes are translated, RNA molecules are active, 
functional elements of the cell whose products can 
detect, interact with, and modify other transcripts. 
Gene expression profiling is the method most 
commonly used thus far to enrich our understanding 
of the molecular basis of rheumatoid arthritis in 
adults and juvenile idiopathic arthritis in children. The 
feasibility of this approach for patient classification 
(for example, active versus inactive disease, disease 
subsets) and improving prognosis (for example, 
response to therapy) has been demonstrated over 
the past 7 years. Mechanistic understanding of 
disease-related differences in gene expression must 
be interpreted in the context of interactions with 
transcriptional regulatory molecules and epigenetic 
alterations of the genome. Ongoing work regarding 
such functional complexities in the human genome 
will likely bring both insight and surprise to our 
understanding of rheumatoid arthritis.
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© 2010 BioMed Central LtdOlsen  and  colleagues  [9]  demonstrated  that  peripheral 
blood  mononuclear  cells  (PBMCs)  from  patients  with 
early and late RA showed distinctly different gene expres-
sion  profiles.  This  group  [10]  also  demonstrated  two 
features  of  RA  expression  profiles  that  have  been 
corroborated  in  several,  but  not  all  [11],  subsequent 
studies: (1) differentially expressed genes in RA do not 
reflect  an  orderly,  patterned  immune  response  (for 
example,  as  one  sees  after  immunization  of  healthy 
controls), and (2) many of the differentially regulated genes 
show no apparent immune function at all. Nevertheless, 
the  success  of  microarray  technologies  in  classifying 
patients  has  held  out  the  promise  that  this  approach 
might be used as the basis for diagnostic assays [12], and 
the  field  seems  to  be  approaching  that  point  now.  A 
recent report by van Baarsen and colleagues [13] provides 
an example of the potential for such clinical applications. 
The authors demonstrated that gene expression profiling 
of autoantibody-positive patients (IgM-rheumatoid factor 
(IgM-RF)  and/or  anti-citrullinated  protein  antibodies) 
with arthralgia could distinguish those patients fated to 
develop frank arthritis over a 7-month period.
Gene  expression  profiling  is  also  beginning  to  show 
potential clinical utility for RA in the area of predicting 
responses to therapy, specifically to tumor necrosis factor 
(TNF)-α  blockers.  This  is  a  critical  issue,  given  the 
expense and intrusiveness of these therapies, and the fact 
that as many as 30% of patients do not respond to their 
first TNF inhibitor [14]. In 2006, Lequerrré and colleagues 
[15]  demonstrated  that  responses  to  the  anti-TNF 
monoclonal antibody infliximab can be predicted on the 
basis of gene expression profiling. More recently, Tanino 
and colleagues [16] replicated this finding in a cohort of 
Japanese  patients,  and  validated  their  candidate  bio-
markers (that is, the genes whose expression levels best 
predicted response to therapy) in a prospective cohort, 
while  Koczan  et  al.  [17]  in  Germany  reported  similar 
results with etanercept. However, it is important to note 
that the predictive genes showed no overlap between the 
Japanese and German cohorts. Whether this was due to 
the differences in array platforms, underlying clinical or 
genetic  differences  in  the  two  populations  studied,  or 
differences in how TNF inhibitors are used in the clinical 
setting  in  the  two  countries  is  unclear.  At  the  present 
time, we can only conclude that, while these preliminary 
studies suggest that it may be feasible to develop array-
based prognostic biomarkers, a common, internationally 
applicable set of gene expression biomarkers has yet to 
emerge.  Of  special  interest  is  that  some  of  the  most 
informative  biomarkers  in  each  cohort  emerged  by 
observing  the  dynamics  of  gene  expression  after  the 
initiation  of  therapy.  Our  group  has  found  similarly 
informative gene dynamics in the polyarticular form of 
juvenile  idiopathic  arthritis  (JIA)  [18].  Thus,  future 
studies will need to incorporate gene dynamics as well as 
static studies; it is likely that these dynamic studies will 
also  provide  unprecedented  insight  into  the  biology  of 
response to therapy.
Insights into pathogenesis
While patient stratifications for clinical and therapeutic 
prognoses are useful in themselves, they represent only 
two potential uses of functional genomics as applied to 
RA.  There  remains  considerable  interest  in  using  gene 
expression profiling to better understand disease patho-
genesis and the complex interactions between genes and 
environment  that  are  believed  to  be  the  basis  of  this 
disease [19]. There have already been some surprises, and 
these surprises in themselves demonstrate the value of 
‘discovery science’ uninformed by a specific hypothesis.
An  interesting  observation  that  has  emerged  from 
several  microarray  studies  of  RA  has  been  the  promi-
nence of genes associated with innate immunity. It has 
long been assumed that RA is an autoimmune disease, 
although the initiating or perpetuating autoantigen(s) are 
poorly understood. Gene expression signatures demon-
strating  critical  involvement  of  the  innate  immune 
system suggest a complex interplay between innate and 
adaptive immunity rather than an antigen-driven event 
[20].  Our  own  work  in  the  polyarticular  form  of  JIA 
(which  phenotypically  carries  a  strong  resemblance  to 
adult RA) suggests that a focused look at innate immunity 
may be fruitful [21,22].
Another  interesting  observation,  revealed  first  in  the 
work by Olsen et al. [9], is the finding that many of the 
differentially expressed genes identified in patients with 
RA  (compared  with  healthy  age-  and  sex-matched 
controls) are not genes directly associated with immune 
function  as  we  currently  understand  it.  Differential 
expres  sion of cell cycle regulators, genes encoding signal 
transduction molecules, transcription factors, and DNA 
repair  enzymes  has  been  seen  in  multiple  microarray 
experiments  [10].  Clearly  there  is  a  need  for  further 
experimental work and interdisciplinary cooperation to 
decipher the clues hidden by these findings.
The currently published literature on the use of gene 
expression  profiling  in  RA  has  largely  used  relatively 
straight  forward  computational  biology  approaches  to 
analyze the data. Published studies have used hierarchical 
cluster  analysis  to  classify  patients  (for  example,  van 
Baarsen et al. [13], and van der Pouw Karan et al. [11]) 
and various methods for assigning function (known or 
putative) to groups of differentially expressed genes, but 
only  recently  have  there  been  attempts  to  understand 
disease  pathogenesis  by  linking  differentially  expressed 
genes into interactive regulatory networks [23,24]. This 
approach can be quite powerful in understanding disease 
pathology. Until recently, it was assumed that biological 
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lated by Erdös and Rényi [25]. This theory assumes that 
constituents  in  a  network  (‘nodes’)  are  connected  ran-
domly to other constituents. Furthermore, the number of 
links  between  nodes  is  similar  and  follows  a  Poisson 
distribution related to the number of constituents in the 
system. Over the past 10 years, it has become clear that 
biological systems exhibit features of scale-free networks 
[26,27].  Computer  modeling  derived  from  genome 
sequen  cing, metabolic studies, and known biochemical 
functions of specific proteins suggests that there are both 
‘hubs’ with high connectivity and peripheral nodes with 
significantly  less  connectivity  within  networks.  An 
interesting  feature  of  such  scale-free  networks  is  that 
they are highly resistant to errors or perturbation [28] 
making them highly relevant to the study of disease. In 
homo  geneous systems, disruption of a single node can 
have significant effects on the whole system, since each 
node  has  approximately  the  same  number  of  (linear) 
connec  tions. In contrast, scale-free systems are relatively 
resistant to perturbations because most nodes show only 
limited  connectivity.  Modulation  of  hubs,  however,  has 
significant effects on the system, because of the high levels 
of connectivity of hubs to other parts of the system. This 
can be seen intuitively in a thought experiment with the 
inter  national air traffic system, which also shows a hub-and-
node structure: disruption of traffic into or out of London 
Heathrow  airport  or  John  F  Kennedy  airport  can  have 
serious ramifications for international travelers all over the 
world, while disruption in Rapid City, South Dakota, or 
Burlington, Vermont, has a significantly smaller impact.
We have found that the complex relationships between 
products of differentially expressed genes derived from 
childhood rheumatic diseases also demonstrate the ‘hub-
and-node’ structure of physiologic systems [29]. Interest-
ingly, most differentially expressed genes occur as nodes, 
while  genes  represented  in  hubs  frequently  encode 
transcription  factors  and  signaling  molecules  whose 
functions may be modified by post-translational process-
ing rather than by differences in levels of RNA or protein. 
If gene expression profiling is to be used to identify new 
targets for therapy, it may be critical to look at network 
structures in order to identify those places where disrup-
tion is likely to be most effective. While there are serious 
limits  to  ‘off-the-shelf’  network  modeling  programs 
whose databases are derived primarily from the existing 
literature,  they  provide  an  easy-to-use  starting  point 
from  which  one  might  build  more  sophisticated 
computational biology approaches.
Interpreting gene expression profiles: studying 
mechanisms that regulate gene expression
While  considerable  progress  has  been  made,  and  new 
computational resources continue to enrich the utility of 
existing and future gene expression databases, it will also 
be critical to use insight gained from studies of trans  crip-
tional regulation of model organisms to understand the 
meaning of expression profiles in complex diseases such 
as  RA.  In  this  regard,  investigators  have  traditionally 
studied  mechanisms  that  regulate  the  expression  of  a 
limited number of genes, as if the expression of each gene 
were an independent event. However, studies from model 
organisms  have  shown  that,  rather  than  occurring 
independently, transcription of large groups of genes is 
tightly coordinated across the genome [30]. Each step in 
gene  transcription,  including  chromatin  remodeling, 
activa  tion and interactions between transcription factors, 
and  transcriptional  processing,  appears  to  be  elegantly 
orches  trated with complementary processes in other genes.
Related to this issue are mechanisms currently being 
elucidated in the area of epigenetics. Although there are 
redundant mechanisms through which the emergence of 
cell  ‘identity’  and  regulation  of  gene  expression  occur, 
biochemical  alterations  of  DNA  [31]  and  associated 
histones [32] in response to environmental changes appear 
to be critical. However, at this early stage, use of such 
information to treat RA has been limited, and the out-
comes are controversial [33].
Furthermore,  we  are  learning  that  differential  gene 
expression  patterns  in  diseases  such  as  RA  are  also 
coordinated  by  elements  within  the  non-protein-coding 
parts of the genome, formerly referred to as ‘junk DNA’ . 
While  there  is  still  a  great  deal  to  be  learned  about 
functional non-coding elements within the genome, there 
is reason to be optimistic that the systematic efforts of the 
National Institutes of Health ENCODE project, organized 
to  identify  all  the  functional  elements  in  the  human 
genome [34], will provide a platform for the develop  ment 
of novel insights into complex human diseases. Even with 
only  a  small  percentage  of  the  func  tional  elements 
characterized, some startling insights have emerged in the 
preliminary  report  encompassing  the  pilot  phase  of  the 
project  [35].  Rather  than  transcripts  merely  serving  as 
passive templates from which genes are translated, RNA 
molecules of eukaryotic organisms are active, functional 
elements of the cell whose products detect, interact with, 
and  modify  other  transcripts.  The  abundance  of  long 
intergenic  non-coding  RNAs  has  added  to  our  under-
standing of the complexity of trans  criptional control [36], 
and it can be anticipated that study of these new regulators 
in the context of complex human diseases will be highly 
informative.  Similarly,  study  ing  small  non-coding  RNAs 
(small  interfering  RNA,  microRNA)  is  very  likely  to 
provide important insights into the mechanisms behind 
the RA gene expression profiles already generated [37,38]. 
Collectively, these mole  cules are likely to transform our 
understanding of the dysregulation of gene expression in 
RA and other rheumatic diseases.
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that are emerging from the ENCODE project to under-
stand the pathology of RA at the molecular level, then we 
have very likely reached the limits of what we can achieve 
while studying mixed populations of cells (except for the 
development  of  biomarkers  and  prognostic  assays).  A 
problem in interpreting many of the published studies of 
gene expression profiling in RA patients is the fact that 
the profiles have typically been generated from PBMCs, a 
mixed  population  of  cells  that  includes  monocytes,  T 
cells, B cells, and natural killer cells. Relatively pure sub-
populations  of  cells  of  the  innate  or  adaptive  immune 
systems from patients with RA have been used in only 
limited cases [39,40]. Epigenetic markers (DNA methy-
lation, histone modifications, non-coding RNA expression, 
and  so  on)  are  also  cell  specific.  In  order  to  derive  a 
mechanistic understanding of how gene transcription is 
regulated  over  the  course  of  RA  -  for  example,  in 
response  to  therapeutic  agents  -  it  will  be  critical  to 
observe  these  changes  over  time  in  specific  cell  types, 
preferably in conjunction with a simultaneously obtained 
gene  expression  profile.  Genome-wide  mapping  of 
disease-specific  transcription  factor  binding  sites  by 
chromatin  immunoprecipitation  (ChIP)-chip  or  ChIP-
sequencing,  particularly  for  those  transcription  factors 
found to be hubs using systems biology approaches, is 
likely to provide crucial insight into RA gene expression 
profiles. As these new results unfold, we may begin to 
regard RA less as an autoimmune disease that is triggered 
by inappropriate recognition of a self antigen by a T cell, 
but,  rather,  as  a  disease  characterized  by  loss  of 
transcriptional  regulation  in  cells  of  both  innate  and 
adaptive immunity.
Conclusions
The past 7 years have shown us the promise of using 
functional genomics to gain insight into the prognosis 
and  pathogenesis  of  RA.  The  future  will  likely  take 
investigators in two very different directions. Pros  pec-
tive validation of prognostic biomarkers of therapeutic 
response  will  build  on  the  promising  work  of  several 
groups  and  facilitate  the  development  of  relatively 
simple, clinically useful assays [41]. Meanwhile, rheuma-
tology investigators, computational biologists, and cell 
biologists  focused  on  transcriptional  regulation  will 
take on the challenge of interpreting the complex biology 
reflected in existing RA gene expression data  bases and 
those to be generated in single-cell populations in the 
near future.
As the American College of Rheumatology indicates, 
finding a cure for RA may be ‘within our reach’. We think, 
however, that the state of the art is better summarized by 
the 1980s rock duo Timbuk3, ‘The future’s so bright, I 
gotta wear shades’ [42].
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